^
    Back
    Association details:
    Biomarker:CCNA2 overexpression
    Cancer:Breast Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer

    Published date:
    04/09/2021
    Excerpt:
    ...the expression of CCNA2 was increased in metastatic breast cancer compare with non-metastatic breast cancer, who underwent immunotherapy....CCNA2 identified as a potential immune therapy marker in breast cancer
    DOI:
    10.2147/OTT.S296373